GlassScriptPhysician profile
Yoany Guia
NPI 1104275973
$3,628.25
in general payments reported to CMS, 2019-2025
28 companies · $561 in 2025
The $561 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $710 · 2021: $166 · 2022: $242 · 2023: $554 · 2024: $955 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $487.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $419.19 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $383.28 | 2019-2022 | |
| Amgen INC. | $330.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $288.79 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $288.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.44 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $227.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.53 | 2022-2025 | |
| Lilly USA, LLC | $116.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $103.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.50 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.46 | 2023 | Rexulti, Jynarque |
| Novartis Pharmaceuticals Corporation | $47.03 | 2023 | |
| Abbott Laboratories | $34.90 | 2022-2023 | Proclaim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $33.97 | 2023-2024 | Qutenza |
| Idorsia Pharmaceuticals US INC | $30.29 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $30.14 | 2025 | Lumryz |
| Exact Sciences Corporation | $28.34 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $28.00 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $27.13 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $24.09 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $23.54 | 2025 | General - Pain Management |
| Grifols USA, LLC | $22.79 | 2024 | Prolastin-C Liquid |
| Dexcom, INC. | $19.29 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $18.21 | 2025 | Korlym |
| Amarin Pharma, INC. | $17.40 | 2020 | |
| Shield Therapeutics INC | $15.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoany Guia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.